XILIO THERAPEUTICS INC (XLO)
US98422T1007 - Common Stock
These stocks are moving in today's session
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab,...
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024
XLO stock results show that Xilio Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ:XLO) just reported results for the second quarter of...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with...
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024
XLO stock results show that Xilio Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite...
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
XLO stock results show that Xilio Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ:XLO) just reported results for the fourth quarter of...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!